UDCA, a licensed agent for primary biliary cholangitis, antagonized hypoxic HCC cell–induced angiogenesis and inhibited the upregulation of HIF-1α, VEGF, and IL-8. Here, CXCL8 is linked to biliary liver cirrhosis.